The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer

Summary

This study aims to evaluate the possible beneficial role of coenzyme Q10 against oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.

Eligibility

Inclusion Criteria:

* Patients with histologically confirmed diagnosis of Stage III colorectal cancer.
* Patients who will be scheduled to receive modified FOLFOX-6.
* Patients with no contraindication to chemotherapy.
* Males and females aged ≥ 18 years old.
* Adequate baseline hematologic values (absolute neutrophilic count ≥ 1.5 × 109 /L, platelet count ≥ 100 × 109 /L and hemoglobin level ≥ 10 g/dl).
* Patients with adequate renal function (serum creatinine \< 1.5 mg/dl
* Patients with adequate liver function (serum bilirubin \< 1.2 mg/dl).
* Patients with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG) score.
* Patients who may receive medications to counteract chemotherapy induced neuropathic pain (gabapentin, lamotrigine, carbamazepine, etc….).

Exclusion Criteria:

* Exclusion criteria

  * Patients with prior exposure to neurotoxic agents (Cisplatin, vincristine, paclitaxel, docetaxol, foscarnet, INH, etc..) in the last 6 months.
  * Patients with evidence of metastasis at the initial assessment.
  * Concomitant use of antioxidant vitamins (vitamin A, C, E),
  * Preexisting peripheral neuropathy resulting from other causes such as diabetes and brain disorders, hypothyroidism, autoimmune diseases, hepatitis C.
  * Patients with diabetes.
  * Patients with inflammatory diseases (ulcerative colitis, rheumatoid arthritis).
  * Patients with stressful conditions as smoking, COPD, ….
  * Patients with active liver disease (cirrhosis, fatty liver, hepatitis C, etc..).
  * Patients with myopathy
  * Patients with renal impairment, including those with end-stage renal disease and those receiving dialysis.
  * Pregnant and breast feeding women.
  * Concurrent use of diltiazem, metoprolol, enalapril, nitroglycerin, warfarin, clopidigrel, aspirin, statins, fibrates, tricyclic antidepressant medications,

Conditions2

Interventions5

Related trials

• A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors — Qilu Pharmaceutical Co., Ltd.
• A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer — Astellas Pharma Global Development, Inc.
• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors — Seagen, a wholly owned subsidiary of Pfizer
• Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) — Merck Sharp & Dohme LLC
• First in Human Study of AZD9592 in Solid Tumors — AstraZeneca
• Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) — EMD Serono Research & Development Institute, Inc.
• A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma — AstraZeneca
• A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States — BeOne Medicines

Browse More Trials